RNATICS Secures €2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development
RNATICS GmbH has been awarded €2.7 million in funding from the Federal Ministry of Research, Technology and Space (BMFTR). The grant supports the next stage of clinical development for RCS-21, a first-in-class inhaled RNA therapeutic targeting severe inflammatory-fibrotic lung diseases.
RCS-21 uses proprietary carbohydrate conjugation for selective uptake into pulmonary macrophages, where it inhibits microRNA-21 – a key driver of pathological inflammation and fibrosis. The program focuses on patients with idiopathic pulmonary fibrosis (IPF) and related fibrotic lung conditions which currently have limited therapeutic options.
More at: www.rnatics.com
This funding marks a major milestone. It allows us to validate our macrophage-targeted platform and moves RCS-21 closer to clinical proof-of-concept for patients suffering from severe pulmonary fibrosis.”
This funding will allow us to make substantial progress in the clinical development of RCS-21. Taking another step towards clinical trials is an important milestone for the translation of our research.